Targeting multiple angiogenic pathways simultaneously: Experience with nintedanib in non-small-cell lung cancer

Greg Durm, Nasser Hanna

Research output: Contribution to journalArticle

4 Scopus citations


Angiogenesis plays a major role in the growth and progression of non-small-cell lung cancer (NSCLC), and there is increasing interest in the development of therapies that block this particular aspect of tumorigenesis. Bevacizumab was the first US FDA-approved inhibitor of angiogenesis after demonstrating improved progression-free survival and overall survival in combination with chemotherapy in treating NSCLC. However, the benefit of bevacizumab is only modest and transient as the tumors inevitably develop resistance to this particular treatment. Therefore, new therapies are being developed that attempt to inhibit angiogenesis through several different pathways. One promising new drug, nintedanib, is an oral triple angiokinase inhibitor that acts by blocking not only VEGFR, but also FGFR and PDGFR, which are involved in the development of resistance to bevacizumab. This article discusses the rationale for this approach and summarizes the clinical trial data on nintedanib, including the two most recent Phase III trials.

Original languageEnglish (US)
Pages (from-to)1167-1173
Number of pages7
JournalFuture Oncology
Issue number7
StatePublished - May 2014



  • angiogenesis
  • FGFR
  • nintedanib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this